🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are on the rise globally, with estimates suggesting more than 82 million infections each year. Notably increased rates are observed in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". A tracking program revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This authorization marks a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Results and Worldwide Availability

As per data released by a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses an injection and a pill. The research involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors on the front lines have shared optimism. The availability of a one-pill regimen like this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea around the world.